Salarius Pharmaceuticals (SLRX) – Analysts’ Recent Ratings Changes

Salarius Pharmaceuticals (NASDAQ: SLRX) recently received a number of ratings updates from brokerages and research firms:

• 12/22/2025 – Salarius Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/16/2025 – Salarius Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/10/2025 – Salarius Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/6/2025 – Salarius Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/4/2025 – Salarius Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/28/2025 – Salarius Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/21/2025 – Salarius Pharmaceuticals is now covered by analysts at Weiss Ratings. They set a “sell (e+)” rating on the stock.

Salarius Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults.